These results suggest that NAM as an adjuvant can enhance Olaparib efficacy by increasing T cell NAD+ levels, further activating the STING axis, thereby enhancing T cell anti-tumor function, providing a novel strategy for OC treatment. Here, STING1 is linked to neoplasm.